Purified Anti-human CD38 Antibody *HIT2*
HIT2 is an anti-human monoclonal antibody that targets the CD38 antigen. CD38 (alternatively called T10) is a 45 kD transmembrane protein that is found on the surface of cells such as NK cells, macrophages and stem cells. CD38 is a component of vital cellular pathways, namely, the apoptotic signaling pathway and B cell receptor signaling pathway. In addition, in certain organisms, it represses apoptotic process, is a positive regulator of cell growth and is an enhancer of vasoconstriction. From a research standpoint, it is of biological interest due to its association with critical macromolecules/ligands like HLA Class II, CD31, CD16 and Hyaluronic acid. CD38 is a fairly uncommon antibody target, with a little more than 10000 publications in the last decade. Even still, CD38 has been widely used in immunology research, commonly serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography.
Conjugation
We provide custom conjugation services for this antibody (eg. labeling of cd38 antibody with HRP). A list of available labels can be found in the table below:
For additional information about custom conjugations, please consult our services page here.
AF | AF350, AF488, AF555, AF594, AF647, AF680, AF700, AF750 |
Proteins | HRP, Alkaline Phosphatase, Streptavidin |
Tandems | APC, APC/Cy7, APC/AF750, APC/iFluor™ 700, APC/iFluor™ 750, PE, PE/Cy5, PE/Cy7, PE/AF610, PE/AF700, PE/iFluor™ 594, PE/iFluor™ 647, PE/iFluor™ 700, PE/iFluor™ 750, PE/Texas Red®, PerCP, PerCP/Cy5.5 |
Small Molecules | Biotin |
Traditional Dyes | FITC (fluorescein), TRITC, PacBlue, PacOrange, Cy3, Cy5 |
iFluor | 350, 405, 430, 450, 488, 514, 532, 546, 555, 560, 568, 594, 610, 633, 647, 660, 670, 680, 700, 710, 750, 790, 800, 810, 820, 840, 860, A7 |
mFluor | UV375, UV460, Violet 450, Violet 500, Violet 510, Violet 540, Blue 570, Green 620, Red 700, Red 780 |
For additional information about custom conjugations, please consult our services page here.
Page updated on December 3, 2024